The PREDICT study investigators are conducting a Phase 4 interventional trial to assess the effect of using a new risk score for persons with hemophilia A transitioning from a standard half life (SHL) FVIII to an extended half life FVIII product (Jivi® [antihemophilic factor (recombinant), PEGylated-aucl]). The study may help to determine the most appropriate prophylaxis dosing regimen when switching factor VIII products. 

This is a 6-month study which is currently recruiting and open to males and females ≥12 years of age with hemophilia A of any disease severity on prophylaxis for which study drug is provided. The study design requires few visits and blood draws. Its outcome is intended to provide helpful information to the community on the care and management of patients with hemophilia A. If you are interested in becoming a treatment site or wish to refer a patient, please contact Bayer using the information below. 

PREDICT Study Website

Additional Resources

Prescribing Information

For more information about this study or to submit a request to speak to a medical expert, please visit  Prophylaxis regimen for hemophilia A patients (  
In addition, you may also contact Jessica Charlet at [email protected] or telephone (412) 660-6440.

Sponsored by: